Filing summary
Entity and period: The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. It is a Form 10-Q for the quarter ended September 30, 2022, filed November 14, 2022. Financial amounts below are in U.S. dollars; tables present amounts in millions unless stated otherwise.
Business context and developments
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, DKN-01, is an investigational monoclonal antibody; it has not been approved by the FDA. Leap retains DKN-01 rights outside Asia (excluding Japan), Australia, and New Zealand, where BeiGene holds an exclusive option and license.
During the period, the company reported clinical data presentations and first-patient enrollment in Part C of the DisTinGuish study and the Phase 2 DeFianCe colorectal cancer study.
Key financial results
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| License revenue | $0 | $0.375 | $0 | $1.125 |
| Research and development expense | $12.102 | $10.077 | $33.931 | $24.090 |
| General and administrative expense | $3.186 | $2.438 | $8.889 | $7.973 |
| Total operating expenses | $15.288 | $12.515 | $42.820 | $32.063 |
| Net loss | $15.094 | $11.139 | $42.494 | $29.799 |
| Net loss per share, basic and diluted | $0.13 | $0.14 | $0.38 | $0.39 |
The company has no product sales and no reported gross margin. License revenue in the prior-year periods came from amortization of BeiGene’s upfront payment; it was fully recognized by December 31, 2021. Q3 2022 included $0.360 million interest income, $0.652 million Australian R&D incentive income, and a $0.807 million foreign currency loss.
Liquidity, cash flow and debt
- Cash and cash equivalents were $78.308 million at September 30, 2022, down from $114.916 million at December 31, 2021. Total assets were $82.165 million and stockholders’ equity was $70.073 million.
- For the nine months, operating cash used was $36.030 million, versus $24.441 million in 2021. Financing cash used was $0.210 million; the prior-year period included $97.280 million financing cash provided, mainly from a public offering. Cash declined by $36.608 million during the 2022 period.
- No borrowings are reported. Total liabilities were $12.092 million, including $0.774 million of operating lease liabilities. The company also disclosed $3.214 million of noncancelable manufacturing commitments.
- Management stated that September 30 cash was expected to fund operating expenses for at least 12 months from issuance of the financial statements. The company expects continuing operating losses and may seek additional financing or collaboration funding.
Material changes, outlook and risks
- Nine-month R&D expense rose $9.841 million year over year, mainly from higher clinical-trial and manufacturing costs, as well as increased payroll and stock-based compensation. Q3 R&D expense increased $2.025 million, primarily due to clinical-trial costs and headcount.
- Nine-month net loss increased $12.695 million year over year. The absence of BeiGene license revenue and higher operating expenses contributed; increased interest income partly offset the impact.
- Management expects R&D spending to increase as DKN-01 development continues, subject to available funding. The filing does not provide specific revenue or profitability guidance and states that clinical-development costs and timing cannot be reasonably estimated.
- On November 2, 2022, Nasdaq notified the company that its share price had been below the $1 minimum bid for 30 consecutive business days. The company had until May 1, 2023 to regain compliance; delisting could affect share liquidity and capital-raising ability.
- Other risks include uncertain clinical outcomes and regulatory approvals, need for additional capital, potential trial delays (including COVID-related impacts), foreign-exchange exposure, and competition. The company reported no material legal proceedings and no material changes to other previously disclosed risk factors.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is for Leap Therapeutics, not the company named in the request metadata.
- Review subsequent cash burn, financing needs, and whether the stated cash runway remains achievable.
- Track DKN-01 trial enrollment, results, timelines, and any BeiGene option exercise, milestone, or royalty developments.
- Verify whether Nasdaq’s minimum-bid compliance was regained by the stated deadline.
- Assess the potential dilution from outstanding warrants, options, and restricted stock units; the filing reports 49.7 million warrants outstanding at September 30, 2022.